Lena S. Abbuehl
Eveline Hofmann2†
Arsany Hakim
Anelia Dietmann- 1Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- 2Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- 3Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Herpes simplex virus (HSV) and varicella zoster virus (VZV) are among the most commonly diagnosed infectious causes of sporadic encephalitis worldwide. Despite treatment, mortality and morbidity rates remain high, especially for HSV encephalitis. This review is intended to provide an overview of the existing scientific literature on this topic from the perspective of a clinician who is confronted with serious decisions about continuation or withdrawal of therapeutic interventions. We performed a literature review searching two databases and included 55 studies in the review. These studies documented or investigated specifically outcome and predictive parameters of outcome of HSV and/or VZV encephalitis. Two reviewers independently screened and reviewed full-text articles meeting the inclusion criteria. Key data were extracted and presented as a narrative summary. Both, HSV and VZV encephalitis have mortality rates between 5 and 20% and complete recovery rates range from 14 to 43% for HSV and 33 to 49% for VZV encephalitis. Prognostic factors for both VZV and HSV encephalitis are older age and comorbidity, as well as severity of disease and extent of magnetic resonance imaging (MRI) lesions on admission, and delay in treatment initiation for HSV encephalitis. Although numerous studies are available, the main limiting factors are the inconsistent patient selection and case definitions as well as the non-standardised outcome measures, which hampers the comparability of the studies. Therefore, larger and standardised observational studies applying validated case definitions and outcome measures including quality of life assessment are required to provide solid evidence to answer the research question.
1. Introduction
Encephalitis is an inflammatory disease of the central nervous system (CNS), sometimes associated with meningitis, neuritis, radiculitis and/or myelitis (1). The estimated annual incidence of all types of encephalitis worldwide is between 1 and 14 cases per 100,000 (2–5). Clinically, encephalitis is defined as altered mental status lasting for ≥24 h, accompanied by evidence of brain parenchymal inflammation. This includes fever, new-onset seizures, focal neurological signs, cerebrospinal fluid (CSF) pleocytosis and/or abnormal findings in magnetic resonance imaging (MRI) or on electroencephalography (EEG) (1). Viral encephalitis is a serious condition with overall mortality rates of up to 30% depending on the causal agent in non-tropical regions (6–8). Up to 75% of long-term survivors of infectious encephalitis have persisting signs and symptoms that significantly impair their quality of life, including cognitive deficits, behavioural and speech disorders, epileptic seizures, frequent headaches and fatigue (7, 9, 10). The socioeconomic impact of infectious encephalitis is considerable: one quarter to half of the patients who were previously employed are unable to return to work (7, 9, 11).
Herpes simplex virus (HSV) encephalitis is the most commonly diagnosed viral encephalitis in industrialised nations (3, 6, 11–14). Besides being one of the most frequent causes, HSV infections of the CNS are also among the most severe of all viral infections of the human brain (14). Typically, after a prodromal phase, patients present with non-specific signs and symptoms such as seizures, abnormal behaviour, impaired consciousness and focal neurological deficits (15). Untreated HSV encephalitis has very high mortality rates of up to 70 and 97% of survivors do not regain their previous level of function (14). The introduction of aciclovir treatment has significantly improved outcome following HSV encephalitis (16, 17).
Another important and treatable herpes virus causing encephalitis is the varicella zoster virus (VZV) (1, 6, 11). Chickenpox is the primary form of VZV infection, occurring mainly in children, and herpes zoster due to reactivation of the virus occurs mostly in adults (3). Less common manifestations of VZV reactivation, and rarely of primary infection, affect the CNS and peripheral nervous system (PNS). They include encephalitis, meningitis, cerebellitis, myelitis and vasculopathy/stroke as well as radiculopathy, peripheral facial palsy and Ramsay Hunt syndrome (18).
In the emergency ward, as soon as viral encephalitis is suspected, the question of outcome and prognosis arises. Knowledge of estimated outcome and prognostic markers is important to optimise case-specific treatment, clinical care and patient information. Many studies, most of them retrospective, have investigated clinical presentation, course of disease including mortality rates and the clinical outcome in survivors. A wide variety of factors – from presenting clinical signs and symptoms, age, comorbidities, interval between onset and hospital admission or initiation of treatment, laboratory parameters and imaging features – have been studied to assess their value as prognostic factors.
As a consultant neurologist working in an intensive care unit (ICU), one must not only be able to inform patients and relatives about the prognosis and expected long-term consequences, but one is also confronted with serious decisions about the continuation or withdrawal of life-sustaining therapies depending on the clinical severity of CNS infections. Against this background, this review is intended to summarise the existing literature and provide an overview of the scientific basis that can be used to assist in making these momentous decisions.
2. Methods
We searched MEDLINE/PubMed (National Library of Medicine) for relevant literature and the Cochrane Library for randomised controlled trials on viral encephalitis caused by HSV or VZV describing clinical outcome or prognostic factors published from 1996 to December 2022. Only reports of research in humans were included. The search terms, selection and exclusion of literature are listed in Supplementary Figure S1. Furthermore, we searched the reference lists of the publications included to identify additional studies not detected in the initial search.
2.1. Eligibility criteria
Studies were included if they were case-series including more than 10 patients, case–control studies, cohort studies or randomized-controlled trials. We included publications that reported on cases with features of encephalitis or meningoencephalitis that were suspected or confirmed to have been caused by HSV or VZV. Diagnosis had to be confirmed by detection of HSV or VZV in the CSF by polymerase chain reaction (PCR) (5, 19). Patients without PCR or serological microbiological confirmation had to be distinguishable in the final analysis. We excluded studies focusing on other causes of infectious encephalitis or meningoencephalitis, autoimmune mediated encephalitis or non-CNS syndromes, such as isolated myelitis or radiculitis. Inclusion criteria were publication in German or English language and the availability of the full text. Studies performed solely in children were also excluded as childhood cases are likely to represent clinical entities that are distinct from adult cases.
2.2. Data extraction
A detailed review of each study was conducted by two independent researchers (LA and AD), during which the following details were extracted: number of patients, cause of encephalitis or meningoencephalitis, clinical syndrome, age, abnormal investigation findings including MRI, outcome measures, factors tested for correlation with outcome and study results. We had a particular interest in publications in which MRI findings were used as markers for prognosis. The CSF parameters we considered applicable were those identified by routine testing, such as protein, glucose, white cell count, or differential cell counts. We recorded MRI abnormalities likely due to encephalitis or meningoencephalitis, or any MRI abnormality if these details were not specified.
3. Results
3.1. Herpes simplex encephalitis
The studies reviewed are summarised in Table 1 and included 32 retrospective and 8 prospective studies from Europe (France, Denmark, Sweden, Spain, Turkey, Czech Republic, Austria), the United States, Israel, Asia (India, Republic of Korea, Japan, China) and New Zealand. Two multinational studies included data from Arabic countries (Egypt, Iraq, Lebanon) (37, 38). In most studies, the proportion of HSV1 to HSV2 infections was evident. The outcome was generally assessed at discharge and during follow-up periods of 3 to 6 months and/or after 1 year. Eight studies had further follow-up periods of up to 2 years (7, 11, 27, 34, 35, 43, 50) or even up to 11 years (20, 21, 50).
Table 1. Reports with data on outcome and/or prognostic factors for HSV or VZV encephalitis.
Mortality rates of HSV encephalitis reported in these studies were mostly between 5 and 20% (7, 11, 20, 22–24, 28, 30–38, 42, 46, 47, 49, 50, 52). Tan et al. described significantly increased mortality rates in immunocompromised compared to immunocompetent patients (36 versus 7%) (30). However, three studies reported no fatal cases (40, 53, 54), whereas five other studies found mortality rates of 24–64% (8, 27, 39, 41, 51). It is noteworthy that the studies reporting no mortality are most likely to have included more of the less severely affected patients. Kaewpoowat et al. (54) included 75% patients characterised as having meningitis and Kim et al. (40) reported a mean initial Glasgow Coma Scale (GCS) of 13.2 with altered mental status – a defining criterion for encephalitis – in only 25% of patients. Růžek et al. (53) did not provide further details on the clinical presentation of the study population and only divided the study population retrospectively into two groups: “mild” following successful uncomplicated therapy with good outcome or “severe” describing a severe course accompanied by acute neurological signs. On the other hand, large studies with mortality rates between 10 and 17% (47–49) included admission to the ICU as an inclusion criterion for study participation.
Outcome was reported to be favourable in 29–65% of survivors (8, 20, 22–24, 27, 29, 31–33, 37, 38, 40, 48, 49, 52, 53) and complete recovery was observed in 14–43% (7, 11, 22–24, 32, 33, 40, 51, 52). Interestingly, one prospective treatment study investigated an additional 3-month course of valaciclovir after standard aciclovir treatment. The authors described no or only mild residual neurocognitive deficits after 12 and 24 months in 86 and 90% of patients in the treatment and control group, respectively (34). A nationwide registry cohort study from Denmark noted a significantly increased risk of mortality (19% 1-year absolute excess mortality) in the first year and an increased risk of dementia in the first 5 years after detection of HSV in the CSF (50).
The factors most frequently associated with mortality and morbidity were age (8, 20, 22, 24, 28, 31, 37, 41, 42), pre-existing morbidity (7, 11, 42, 54), fever on admission (31, 47) and duration of fever after start of treatment (28), as well as lower GCS or a higher acute physiology and chronic health evaluation (APACHE) score on admission (8, 22, 24, 41). The following clinical parameters were also found to be associated with a worse outcome: longer interval between onset of main symptoms and hospitalisation (32), pre-existing immunocompromised state (30, 74) and status epilepticus, persistence of impaired consciousness, confusion or aphasia at day 5 of evolution (52), admission-to-MRI delay (52), need for mechanical ventilation (47) and length of stay in the ICU (52). Interestingly, direct admission to the ICU seems to be protective (47).
Development of autoimmune encephalitis (AE) within 3 months after HSV encephalitis has been described in up to 27% of cases (74% N-methyl-D-aspartate (NMDAR), 26% unknown antigens) (36, 43). Risk factors were younger age (≤4 years) and shorter interval between HSV encephalitis and detection of AE antibodies (43). Early detection of anti-NMDAR antibodies was associated with an overall increase in inflammatory CSF response and worse outcome (35, 36).
Regarding laboratory parameters, lower CSF cell count and initially negative HSV PCR were found to be associated with worse outcome in immunocompromised patients (30). Interestingly, another study noted that of 273 HSV encephalitis patients, 11 had negative HSV PCR in the first lumbar puncture performed 1 day after symptom onset (49). An initial negative HSV PCR was associated with worse outcome. In-hospital mortality was 27% and modified Rankin Scale (mRS) ≥4 at 3 months in 73% of PCR-negative patients compared to 14 and 33%, respectively in PCR-positive HSV encephalitis patients. This difference was only partially explained by delayed start of aciclovir treatment (49). Controversially, Mulatero et al. reported that 13% (11/76) of patients had negative HSV PCR in the first lumbar puncture performed – mean 1.8 ± 3 days (range 0–17 days) – after admission (52). These patients had less severe disease, but no difference was seen in the outcome (52). Overall, studies reported between 4 and 13% initial false negative HSV PCR results (41, 47, 49, 52).
Levels of neurofilament (NFL) in CSF (36) and serum albumin levels on admission (28) have been associated with outcome. No direct correlation between viral load in CSF and clinical outcome has been found (8, 23, 27, 53). Xanthochromia (haem degradation products in the CSF leading to a yellowish appearance) is a rare condition in HSV encephalitis (38) and is associated with poor outcome (8). Most likely, xanthochromia reflects advanced brain infection with tissue necrosis (34).
Several studies mention imaging findings (33), of these, nine studies described them in more detail or focused on MRI findings and their prognostic value (32, 39–41, 44, 47, 48, 52), as summarised in Table 2. Extent of brain involvement seen on MRI at admission, especially bilateral temporal lobe involvement, has been described as a factor associated with poor prognosis (32). The study by Sili et al. (32) has limitations due to missing information on time from hospital admission to MRI, lack of detailed description of abnormal MRI sequences and the high proportion of “suspected” HSV encephalitis (48% of the study population). However, it has been confirmed that fluid-attenuated inversion recovery (FLAIR) MRI signal abnormalities affecting more than three brain lobes, as well as the presence of diffusion-weighted MRI signal abnormalities in the left thalamus, were independently associated with poor outcome (47, 48). The multicentre studies by Jaquet et al. (47) and Sarton et al. (48), analysed large cohorts of patients with a well-described study population. Both these studies (47, 48) analysed the same cohort of HSV encephalitis patients requiring ICU treatment; however, Sarton et al. (48) included fewer patients in their analysis and focused exclusively on MRI and functional outcomes after HSV encephalitis. In these two studies, the MRI acquisition took place a median of 3 days after hospital admission and 1 day after ICU admission and it was abnormal in 99.3% of patients, with FLAIR hyperintensities as the most important finding (48). Singh et al. also showed that restricted diffusion on MRI was associated with poor outcome (mRS ≥3) in elderly people (median age 66 years) at hospital discharge as well as 6–12 months later (41). In contrast, other studies showed no association between MRI findings and outcome (40, 55). The studies by Kim et al. (40) and Jordan et al. (55) both included a retrospective analysis, of 25 and 15 patients, respectively. In the study by Kim et al. (40) there was a surprisingly low number of abnormal MRI (64% FLAIR and 59% diffusion-weighted imaging (DWI)) compared to larger studies (32, 48). However, the authors did not explicitly report the proportion of normal and abnormal MRI in HSV patients and the value of the study is therefore limited.
Table 2. Reports with MRI data from patients with HSV encephalitis.
Delay of aciclovir initiation significantly worsens clinical outcome (20–22, 30, 32, 37, 41). However, a dosage of aciclovir that is higher than the recommended standard dose of 10 mg per kg body weight every 8 h together with an additional course of oral valaciclovir therapy after aciclovir treatment did not improve outcome (29, 34). Very recently Mulatero et al. described an association between worse outcome, body weight and aciclovir dosage and suggested a weight-adjusted dose regimen, increasing the dose for patients with lower body weight (of <79 kg) up to 15 mg/kg body weight, especially for patients with a body weight below 57 kg (52). The question whether additional treatment with corticosteroids is beneficial for long-term outcome has yet to be answered (24, 45, 75). In one prospective randomized, double-blind, placebo-controlled treatment trial that had to be stopped prematurely due to slow recruitment, adjunctive steroid treatment did not affect mortality or neurological sequelae (45).
3.2. Varicella zoster virus encephalitis
As mentioned above, VZV causes a wide range of clinical manifestations of infection of the nervous system. Most frequently VZV infection or reactivation affects the PNS causing ganglionitis and dermatomal rash or facial nerve palsy (64). Less frequently, patients present with encephalitis, meningitis, cerebellitis, myelitis, or stroke/vasculopathy (59, 60, 64, 76, 77). Therefore, VZV infection can usually be discriminated clinically from HSV infection by the typical rash – if present – and the clinical presentation. However, no clinical sign or symptom can discriminate clinically between VZV and HSV encephalitis in the very early phase.
In this review, we focus on studies investigating outcome and prognosis after an encephalitic or meningitic course of VZV infection. Studies exclusively investigating outcome after PNS infection, herpes zoster or after vasculopathy are beyond the scope of this review. We included 22 studies (16 retrospective, 6 prospective) from 12 countries worldwide into the review, as summarised in Table 1. The outcome was generally assessed at discharge, some studies had follow-up periods of 1 to 6 months and/or after 1–3 years.
Encephalitis and meningitis due to VZV infection has a mortality rate of 0–15%, with fatal cases more likely during an encephalitic disease course (11, 34, 43, 53, 54, 57, 59, 62–64, 67–70). Only two studies reported mortality rates as high as 33% (72) and 36% (70). The first of these included only patients with severe encephalitis requiring intensive care (median GCS at admission 12, and mechanical ventilation in 84%) (72). In the second study, all the patients who died had a meningoencephalitic course plus stroke and/or myelitis (70).
A precise estimation of clinical outcome of survivors is difficult because of the varying definitions of outcome between the studies, different time points of evaluation (from discharge to follow-up after 3 years). Often outcome is reported combining various clinical manifestations of VZV infection of the CNS, sometimes even including PNS infection. However, the largest prospective study of VZV encephalitis, which included 92 patients, reported full recovery in 49% of patients after 3 months (68). Another study, prospectively investigating various infectious causes and outcomes of encephalitis described complete recovery in 41% of VZV encephalitis patients after 3 years (59). Interestingly, in another publication from the same group, which investigated the overall long-term outcome in patients from the same cohort study on infectious encephalitis, only 33% of VZV patients were found to have made a complete recovery after 3 years (7). A third study, with a retrospective design, worth mentioning here, showed a favourable 1-year outcome (i.e., mRS 0–2) in 36% of the whole study population and in 48% (20/41, excluding patients who died) of ICU survivors (72).
Most studies on VZV meningitis observe a good overall outcome in 70–100% of patients (54, 56, 60, 62, 63, 65, 66, 70, 71), although persisting neurological sequelae in 0 (60, 66) up to 82% (70) of patients have been described in some studies. In a small case–control study on 14 patients with VZV CNS infection (4 with meningitis, 6 with encephalitis and 4 with radiculitis or polyneuropathy) mild cognitive deficits were seen more frequently in a follow-up examination after 3–4 years than in a control group (60).
Prognostic factors for a severe acute disease course are controversial: whereas three studies found that higher VZV DNA load in the CSF was associated with disease severity (57, 58, 63), this was not confirmed in another study (53). In the acute phase, skin rash has been reported in 43–91% of patients (54, 56–58, 63, 65, 67, 68, 70). Only a few studies report herpes zoster in less than 60% of patients (56, 62, 70), occurring in 30–70% before (57, 58, 68), at or after onset of neurological signs and symptoms (57, 58). A shorter interval between appearance of herpes zoster and onset of neurological signs and symptoms has been described as a negative prognostic factor for death or sequelae (65). Older age (11, 67, 68, 70, 72) and pre-existing comorbidities (11, 54, 69, 70), as well as an encephalitic course of disease (54, 56, 68), need for mechanical ventilation (72) or signs of vasculitis (68) were associated with a worse outcome.
A large Danish cohort study analysing data from the national health registry showed that immunosuppressive state and comorbidities (Charlson Comorbidity Index >1) were a risk factor for detecting VZV DNA in the CSF (69). Mortality was increased in this VZV cohort, especially in the first year of observation and in patients with immunosuppressive or comorbid conditions (69). An increased risk of dementia and epilepsy, but not psychiatric disease, was found in the same cohort during the observation period of 12 years (69). Immunosuppression was a risk factor for more severe disease, but was not associated with worse outcome as found in three other studies (65, 70, 72).
MRI findings in patients with neurological VZV infections have been mixed, with pathological findings in 5% up to 70% of meningitis and encephalitis patients during the acute phase (54, 56, 61, 65, 67, 68, 70–72). To our knowledge, MRI findings have not so far been evaluated for their potential to serve as prognostic parameters, most likely due to incomplete data sets and mainly nonspecific MRI findings.
Interestingly, contrary to one prospective study (68) and two retrospective studies (67, 72), Yan et al. recently identified delayed time to aciclovir treatment as an independent risk factor for worse outcome (71). In the study by Le Bot et al., a higher dose of intravenous aciclovir (15 mg/kg every 8 h) was not found to be protective (67).
4. Discussion
Various studies have addressed outcome and prognostic factors in patients with HSV and VZV encephalitis. Since HSV encephalitis is the most common cause of viral encephalitis worldwide, with published case definitions (1), more studies with a reasonable number of study subjects and defined inclusion criteria are available than for VZV encephalitis or meningitis. Most studies had an observational, retrospective design and outcome was assessed mostly over a period of a few months up to 1 year and occasionally up to 3 years or more.
Mortality rates for HSV encephalitis varied significantly, from no mortality (40, 53, 54) to 65% mortality (41), while most studies reported mortality rates between 5 and 20% (7, 11, 22–24, 28, 30–38, 42, 47, 49, 50, 52). For encephalitis and meningitis due to VZV infection, slightly lower mortality rates of 0–15% have been reported (11, 34, 43, 53, 54, 57, 62, 63, 66–70). However, studies that have looked only at an encephalitic disease course found mortality rates of 33–36% (70, 72). Increased overall mortality has been observed within the first year after HSV or VZV encephalitis (50, 68). The outcome data were similarly varied: whereas some studies of HSV encephalitis describe a good (28, 32) or even excellent outcome for survivors (34, 35), other studies have reported high morbidity rates (47, 49). Patients with meningitis associated with VZV infection seems to have a good overall outcome in 70–100% of cases (54, 56, 60, 63, 65, 70, 71), whereas an encephalitic disease course is associated with high rates of long-term morbidity (70, 72). However, rates of complete recovery from HSV and VZV are comparable: around 14–43% for HSV (7, 11, 22–24, 32, 33, 40, 52) and 33–49% for VZV encephalitis (7, 68).
These large differences in mortality and morbidity rates are mainly attributable to the very different study designs and the widely varying definitions of inclusion criteria and studies are often difficult to compare. The lack of standardised inclusion criteria and outcome measures results in inclusion of more or less severely neurologically affected patients and some studies on VZV even combine patients with infection of the CNS and PNS. In addition, the outcome is defined very differently across the studies, which again makes it difficult to draw conclusions. Many studies used the mRS or the GOS; however, the cut-off for favourable and unfavourable outcome, as well as time-points of outcome evaluation were set inconsistently. Only a minority of studies investigated outcome in different functional neurological domains (i.e., neurocognitive, motor residuals, sleep–wake disorders etc.) and subjective impacts of neurological sequelae on daily life from the patient’s perspective have not been studied so far.
Risk or outcome scores are widely used in different medical fields (i.e., ABCD2-score for stroke risk after transient ischemic attack, Ranson’s criteria for pancreatitis mortality etc.). In our literature review, we found no prototype predictive score for estimating long-term clinical outcome for patients with viral encephalitis, comparable to the disability score for children after Japanese encephalitis (78). Most likely, this reflects the non-uniform definition of outcome measures (79).
Neuroimaging features may be essential tools not only to confirm the diagnosis and rule out alternative diagnoses but also to estimate outcome of disease. Whenever available, MRI is clearly preferable to CT for the diagnosis of encephalitis, given its sensitivity and specificity (80–82). The sensitivity of MRI in detecting acute, infectious encephalitis varies according to the causative agent: Overall, 95 to 100% of patients with HSV encephalitis show typical MRI abnormalities (28, 41, 48), therefore, alternative diagnoses should be considered if typical MRI findings are absent. From the largest MRI studies that focused on HSV encephalitis we can conclude that more extensive FLAIR lesions (>3 brain lobes affected) on the MRI acquired on admission are associated with higher mortality and morbidity (47, 48). On the other hand, VZV encephalitis may well be diagnosed despite normal MRI brain scans (55); this may explain why we found no study evaluating the prognostic value of MRI in VZV encephalitis.
To summarise and answer the main question posed in our review, many studies have been performed in patients with HSV and VZV encephalitis. HSV, more than VZV encephalitis, is associated with high mortality and long-term sequelae despite available therapy, and complete remission – at least for up to 3 years – is expected in fewer than half of patients. For further studies it is crucial to standardise inclusion criteria according to the case definitions (13) and use standardised outcome measures to allow comparability. Studies with longer follow-up periods and evaluation of functional impact of persisting sequelae on activities of daily life are also needed.
Author contributions
LA, EH, AH, and AD participated in conception and organisation of review, literature search, and all stages of writing from initial draft to final product. All authors contributed to the article and approved the submitted version.
Funding
AD has been personally funded by academic research grants from the Bangerter Rhyner Stiftung and University Bern. Open access funding was provided by University of Bern.
Acknowledgments
We thank Jonathan and Christina Peace and Susan Kaplan for the thorough English language editing of this manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2023.1130090/full#supplementary-material
References
1. Venkatesan, A , Tunkel, AR , Bloch, KC , Lauring, AS , Sejvar, J , Bitnun, A, et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis. (2013) 57:1114–28. doi: 10.1093/cid/cit458
2. Granerod, J , Tam, CC , Crowcroft, NS , Davies, NWS , Borchert, M , and Thomas, SL . Challenge of the unknown: a systematic review of acute encephalitis in non-outbreak situations. Neurology. (2010) 75:924–32. doi: 10.1212/WNL.0b013e3181f11d65
3. Boucher, A , Herrmann, JLL , Morand, P , Buzelé, R , Crabol, Y , Stahl, JPP, et al. Epidemiology of infectious encephalitis causes in 2016. Médecine Mal Infect. (2017) 47:221–35. doi: 10.1016/j.medmal.2017.02.003
4. Jmor, F , Emsley, HC , Fischer, M , Solomon, T , and Lewthwaite, P . The incidence of acute encephalitis syndrome in Western industrialised and tropical countries. Virol J. (2008) 5:134. doi: 10.1186/1743-422X-5-134
5. Solomon, T , Michael, BD , Smith, PE , Sanderson, F , Davies, NWS , Hart, IJ, et al. Management of suspected viral encephalitis in adults - Association of British Neurologists and British Infection Association National Guidelines. J Infect. (2012) 64:347–73. doi: 10.1016/j.jinf.2011.11.014
6. Granerod, J , Ambrose, HE , Davies, NW , Clewley, JP , Walsh, AL , Morgan, D, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. (2010) 10:835–44. doi: 10.1016/S1473-3099(10)70222-X
7. Mailles, A , De Broucker, T , Costanzo, P , Martinez-Almoyna, L , Vaillant, V , and Stahl, JP . Long-term outcome of patients presenting with acute infectious encephalitis of various causes in France. Clin Infect Dis. (2012) 54:1455–64. doi: 10.1093/cid/cis226
8. Poissy, J , Champenois, K , Dewilde, A , Melliez, H , Georges, H , Senneville, E, et al. Impact of herpes simplex virus load and red blood cells in cerebrospinal fluid upon herpes simplex meningo-encephalitis outcome. BMC Infect Dis. (2012) 12:356. doi: 10.1186/1471-2334-12-356
9. Ungureanu, A , van der Meer, J , Bicvic, A , Abbuehl, L , Chiffi, G , Jaques, L, et al. Meningitis, meningoencephalitis and encephalitis in Bern: an observational study of 258 patients. BMC Neurol. (2021) 21:474. doi: 10.1186/s12883-021-02502-3
10. Dagsdóttir, HM , Sigurðardóttir, B , Gottfreðsson, M , Kristjánsson, M , Löve, A , Baldvinsdóttir, GE, et al. Herpes simplex encephalitis in Iceland 1987–2011. Springerplus. (2014) 3:524. doi: 10.1186/2193-1801-3-524
11. Mailles, A , and Stahl, JP . Infectious encephalitis in France in 2007: a national prospective study. Clin Infect Dis. (2009) 49:1838–47. doi: 10.1086/648419
12. Granerod, J , Cousens, S , Davies, NWS , Crowcroft, NS , and Thomas, SL . New estimates of incidence of encephalitis in England. Emerg Infect Dis. (2013) 19:1455–62. doi: 10.3201/eid1909.130064
13. Tunkel, AR , Glaser, CA , Bloch, KC , Sejvar, JJ , Marra, CM , Roos, KL, et al. The Management of Encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. (2008) 47:303–27. doi: 10.1086/589747
14. Whitley, RJ . Herpes simplex encephalitis: adolescents and adults. Antivir Res. (2006) 71:141–8. doi: 10.1016/j.antiviral.2006.04.002
15. Bradshaw, MJ , and Venkatesan, A . Herpes simplex virus-1 encephalitis in adults: pathophysiology, diagnosis, and management. Neurotherapeutics. (2016) 13:493–508. doi: 10.1007/s13311-016-0433-7
16. Whitley, RJ , Alford, CA , Hirsch, MS , Schooley, RT , Luby, JP , Aoki, FY, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. (1986) 314:144–9. doi: 10.1056/NEJM198601163140303
17. Sköldenberg, B , Alestig, K , Burman, L , Forkman, A , Lövgren, K , Norrby, R, et al. Acyclovir versus vidarabine in herpes simplex encephalitis. Lancet. (1984) 2:707–11. doi: 10.1016/S0140-6736(84)92623-0
18. Gershon, AA , Breuer, J , Cohen, JI , Cohrs, RJ , Gershon, MD , Gilden, D, et al. Varicella zoster virus infection. Nat Rev Dis Prim. (2015) 1:15016. doi: 10.1038/nrdp.2015.16
19. Taba, P , Schmutzhard, E , Forsberg, P , Lutsar, I , Ljøstad, U , Mygland, Å, et al. EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis. Eur J Neurol. (2017) 24:1214–e61. doi: 10.1111/ene.13356
20. McGrath, N , Anderson, NE , Croxson, MC , and Powell, KF . Herpes simplex encephalitis treated with acyclovir: diagnosis and long-term outcome. J Neurol Neurosurg Psychiatry. (1997) 63:321–6. doi: 10.1136/jnnp.63.3.321
21. Utley, TF , Ogden, JA , Gibb, A , McGrath, N , and Anderson, NE . The long-term neuropsychological outcome of herpes simplex encephalitis in a series of unselected survivors. Neuropsychiatry Neuropsychol Behav Neurol. (1997) 10:180–9. http://www.ncbi.nlm.nih.gov/pubmed/9297711.
22. Raschilas, F , Wolff, M , Delatour, F , Chaffaut, C , De Broucker, T , Chevret, S, et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis. (2002) 35:254–60. doi: 10.1086/341405
23. Kamei, S , Takasu, T , Morishima, T , and Mizutani, T . Serial changes of intrathecal viral loads evaluated by Chemiluminescence assay and nested PCR with Aciclovir treatment in herpes simplex virus encephalitis. Intern Med. (2004) 43:796–801. doi: 10.2169/internalmedicine.43.796
24. Kamei, S . Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry. (2005) 76:1544–9. doi: 10.1136/jnnp.2004.049676
25. Kamei, S , Taira, N , Ishihara, M , Sekizawa, T , Morita, A , Miki, K, et al. Prognostic value of cerebrospinal fluid cytokine changes in herpes simplex virus encephalitis. Cytokine. (2009) 46:187–93. doi: 10.1016/j.cyto.2009.01.004
26. Taira, N , Kamei, S , Morita, A , Ishihara, M , Miki, K , Shiota, H, et al. Predictors of a prolonged clinical course in adult patients with herpes simplex virus encephalitis. Intern Med. (2009) 48:89–94. doi: 10.2169/internalmedicine.48.1445
27. Hjalmarsson, A , Granath, F , Forsgren, M , Brytting, M , Blomqvist, P , and Sköldenberg, B . Prognostic value of intrathecal antibody production and DNA viral load in cerebrospinal fluid of patients with herpes simplex encephalitis. J Neurol. (2009) 256:1243–51. doi: 10.1007/s00415-009-5106-6
28. Riera-Mestre, A , Gubieras, L , Martínez-Yelamos, S , Cabellos, C , and Fernández-Viladrich, P . Adult herpes simplex encephalitis: fifteen years’ experience. Enferm Infecc Microbiol Clin. (2009) 27:143–7. doi: 10.1016/j.eimc.2008.05.006
29. Stahl, JP , Mailles, A , and De Broucker, T . Herpes simplex encephalitis and management of acyclovir in encephalitis patients in France. Epidemiol Infect. (2012) 140:372–81. doi: 10.1017/S0950268811000483
30. Tan, IL , McArthur, JC , Venkatesan, A , and Nath, A . Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology. (2012) 79:2125–32. doi: 10.1212/WNL.0b013e3182752ceb
31. Riancho, J , Delgado-Alvarado, M , Sedano, MJ , Polo, JM , and Berciano, J . Herpes simplex encephalitis: clinical presentation, neurological sequelae and new prognostic factors. Ten years of experience. Neurol Sci. (2013) 34:1879–81. doi: 10.1007/s10072-013-1475-9
32. Sili, U , Kaya, A , and Mert, A, HSV Encephalitis Study Group . Herpes simplex virus encephalitis: clinical manifestations, diagnosis and outcome in 106 adult patients. J Clin Virol. (2014) 60:112–8. doi: 10.1016/j.jcv.2014.03.010
33. Jouan, Y , Grammatico-Guillon, L , Espitalier, F , Cazals, X , François, P , and Guillon, A . Long-term outcome of severe herpes simplex encephalitis: a population-based observational study. Crit Care. (2015) 19:345. doi: 10.1186/s13054-015-1046-y
34. Gnann, JW , Sköldenberg, B , Hart, J , Aurelius, E , Schliamser, S , Studahl, M, et al. Herpes simplex encephalitis: lack of clinical benefit of long-term valacyclovir therapy. Clin Infect Dis. (2015) 61:683–91. doi: 10.1093/cid/civ369
35. Westman, G , Aurelius, E , Ahlm, C , Blennow, K , Eriksson, K , Lind, L, et al. Cerebrospinal fluid biomarkers of brain injury, inflammation and synaptic autoimmunity predict long-term neurocognitive outcome in herpes simplex encephalitis. Clin Microbiol Infect. (2021) 27:1131–6. doi: 10.1016/j.cmi.2020.09.031
36. Westman, G , Studahl, M , Ahlm, C , Eriksson, BM , Persson, B , Rönnelid, J, et al. N-methyl-D-aspartate receptor autoimmunity affects cognitive performance in herpes simplex encephalitis. Clin Microbiol Infect. (2016) 22:934–40. doi: 10.1016/j.cmi.2016.07.028
37. Erdem, H , Cag, Y , Ozturk-Engin, D , Defres, S , Kaya, S , Larsen, L, et al. Results of a multinational study suggest the need for rapid diagnosis and early antiviral treatment at the onset of herpetic meningoencephalitis. Antimicrob Agents Chemother. (2015) 59:3084–9. doi: 10.1128/AAC.05016-14
38. Cag, Y , Erdem, H , Leib, S , Defres, S , Kaya, S , Larsen, L, et al. Managing atypical and typical herpetic central nervous system infections: results of a multinational study. Clin Microbiol Infect. (2016) 22:568.e9–568.e17. doi: 10.1016/j.cmi.2016.03.027
39. Kalita, J , Misra, UK , Mani, VE , and Bhoi, SK . Can we differentiate between herpes simplex encephalitis and Japanese encephalitis? J Neurol Sci. (2016) 366:110–5. doi: 10.1016/j.jns.2016.05.017
40. Kim, YS , Jung, KH , Lee, ST , Kang, BS , Yeom, JS , Moon, J, et al. Prognostic value of initial standard EEG and MRI in patients with herpes simplex encephalitis. J Clin Neurol. (2016) 12:224–9. doi: 10.3988/jcn.2016.12.2.224
41. Singh, TD , Fugate, JE , Hocker, S , Wijdicks, EFMM , Aksamit, AJ , and Rabinstein, AA . Predictors of outcome in HSV encephalitis. J Neurol. (2016) 263:277–89. doi: 10.1007/s00415-015-7960-8
42. Jørgensen, LK , Dalgaard, LS , Østergaard, LJ , Nørgaard, M , and Mogensen, TH . Incidence and mortality of herpes simplex encephalitis in Denmark: a nationwide registry-based cohort study. J Infect. (2017) 74:42–9. doi: 10.1016/j.jinf.2016.09.004
43. Armangue, T , Spatola, M , Vlagea, A , Mattozzi, S , Cárceles-Cordon, M , Martinez-Heras, E, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. (2018) 17:760–72. doi: 10.1016/S1474-4422(18)30244-8
44. Bewersdorf, JP , Koedel, U , Patzig, M , Dimitriadis, K , Paerschke, G , Pfister, H-W, et al. Challenges in HSV encephalitis: normocellular CSF, unremarkable CCT, and atypical MRI findings. Infection. (2019) 47:267–73. doi: 10.1007/s15010-018-1257-7
45. Meyding-Lamadé, U , Jacobi, C , Martinez-Torres, F , Lenhard, T , Kress, B , Kieser, M, et al. The German trial on Aciclovir and corticosteroids in herpes-simplex-virus-encephalitis (GACHE): a multicenter, randomized, double-blind, placebo-controlled trial. Neurol Res Pract. (2019) 1:26. doi: 10.1186/s42466-019-0031-3
46. Oud, L . Herpes simplex virus encephalitis: patterns of epidemiology and outcomes of patients admitted to the intensive care unit in Texas, 2008 - 2016. J Clin Med Res. (2019) 11:773–9. doi: 10.14740/jocmr4025
47. Jaquet, P , de Montmollin, E , Dupuis, C , Sazio, C , Conrad, M , Susset, V, et al. Functional outcomes in adult patients with herpes simplex encephalitis admitted to the ICU: a multicenter cohort study. Intensive Care Med. (2019) 45:1103–11. doi: 10.1007/s00134-019-05684-0
48. Sarton, B , Jaquet, P , Belkacemi, D , De Montmollin, E , Bonneville, F , Sazio, C, et al. Assessment of magnetic resonance imaging changes and functional outcomes among adults with severe herpes simplex encephalitis. JAMA Netw Open. (2021) 4:e2114328. doi: 10.1001/jamanetworkopen.2021.14328
49. de Montmollin, E , Dupuis, C , Jaquet, P , Sarton, B , Sazio, C , Susset, V, et al. Herpes simplex virus encephalitis with initial negative polymerase chain reaction in the cerebrospinal fluid: prevalence, associated factors, and clinical impact. Crit Care Med. (2022) 50:e643–8. doi: 10.1097/CCM.0000000000005485
50. Hansen, A-BE , Vestergaard, H , Dessau, RB , Bodilsen, J , Andersen, NS , Omland, LH, et al. Long-term survival, morbidity, social functioning and risk of disability in patients with a herpes simplex virus type 1 or type 2 central nervous system infection, Denmark, 2000–2016. Clin Epidemiol. (2020) 12:745–55. doi: 10.2147/CLEP.S256838
51. Müller-Jensen, L , Zierold, S , Versluis, JM , Boehmerle, W , Huehnchen, P , Endres, M, et al. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study. Eur J Cancer. (2022) 175:224–35. doi: 10.1016/j.ejca.2022.08.009
52. Mulatero, M , Boucekine, M , Felician, O , Boussen, S , Kaplanski, G , Rossi, P, et al. Herpetic encephalitis: which treatment for which body weight? J Neurol. (2022) 269:3625–35. doi: 10.1007/s00415-022-10981-8
53. Růžek, D , Piskunova, N , and Žampachová, E . High variability in viral load in cerebrospinal fluid from patients with herpes simplex and varicella-zoster infections of the central nervous system. Clin Microbiol Infect. (2007) 13:1217–9. doi: 10.1111/j.1469-0691.2007.01831.x
54. Kaewpoowat, Q , Salazar, L , Aguilera, E , Wootton, SH , and Hasbun, R . Herpes simplex and varicella zoster CNS infections: clinical presentations, treatments and outcomes. Infection. (2016) 44:337–45. doi: 10.1007/s15010-015-0867-6
55. Jordan, B , Kösling, S , Emmer, A , Koch, A , Müller, T , and Kornhuber, M . A study on viral CNS inflammation beyond herpes encephalitis. J Neurovirol. (2016) 22:763–73. doi: 10.1007/s13365-016-0452-5
56. Lee, GH , Kim, J , Kim, HW , and Cho, JW . Herpes simplex viruses (1 and 2) and varicella-zoster virus infections in an adult population with aseptic meningitis or encephalitis: a nine-year retrospective clinical study. Medicine (Baltimore). (2021) 100:e27856. doi: 10.1097/MD.0000000000027856
57. Aberle, SW , Aberle, JH , Steininger, C , and Puchhammer-Stöckl, E . Quantitative real time PCR detection of varicella-zoster virus DNA in cerebrospinal fluid in patients with neurological disease. Med Microbiol Immunol. (2005) 194:7–12. doi: 10.1007/s00430-003-0202-1
58. Persson, A , Bergström, T , Lindh, M , Namvar, L , and Studahl, M . Varicella-zoster virus CNS disease-Viral load, clinical manifestations and sequels. J Clin Virol. (2009) 46:249–53. doi: 10.1016/j.jcv.2009.07.014
59. De Broucker, T , Mailles, A , Chabrier, S , Morand, P , and Stahl, J-P . Acute varicella zoster encephalitis without evidence of primary vasculopathy in a case-series of 20 patients. Clin Microbiol Infect. (2012) 18:808–19. doi: 10.1111/j.1469-0691.2011.03705.x
60. Grahn, A , Nilsson, S , Nordlund, A , Lindén, T , and Studahl, M . Cognitive impairment 3 years after neurological varicella-zoster virus infection: a long-term case control study. J Neurol. (2013) 260:2761–9. doi: 10.1007/s00415-013-7057-1
61. Grahn, A , Hagberg, L , Nilsson, S , Blennow, K , Zetterberg, H , and Studahl, M . Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections. J Neurol. (2013) 260:1813–21. doi: 10.1007/S00415-013-6883-5
62. Hong, HL , Lee, EM , Sung, H , Kang, JK , Lee, SA , and Choi, SH . Clinical features, outcomes, and cerebrospinal fluid findings in adult patients with central nervous system (CNS) infections caused by varicella-zoster virus: comparison with enterovirus CNS infections. J Med Virol. (2014) 86:2049–54. doi: 10.1002/JMV.23902
63. Rottenstreich, A , Oz, ZK , and Oren, I . Association between viral load of varicella zoster virus in cerebrospinal fluid and the clinical course of central nervous system infection. Diagn Microbiol Infect Dis. (2014) 79:174–7. doi: 10.1016/j.diagmicrobio.2014.02.015
64. Skripuletz, T , Pars, K , Schulte, A , Schwenkenbecher, P , Yildiz, Ö , Ganzenmueller, T, et al. Varicella zoster virus infections in neurological patients: a clinical study. BMC Infect Dis. (2018) 18:1–11. doi: 10.1186/s12879-018-3137-2
65. Corral, C , Quereda, C , Muriel, A , Martínez-Ulloa, PL , González-Gómez, FJ , and Corral, Í . Clinical spectrum and prognosis of neurological complications of reactivated varicella-zoster infection: the role of immunosuppression. J Neurovirol. (2020) 26:696–703. doi: 10.1007/s13365-020-00872-x
66. Tabaja, H , Sharara, SL , Abi Aad, Y , Beydoun, N , Tabbal, S , Makki, A, et al. Varicella zoster virus infection of the central nervous system in a tertiary care center in Lebanon. Médecine Mal Infect. (2020) 50:280–7. doi: 10.1016/J.MEDMAL.2019.08.005
67. Le Bot, A , Ballerie, A , Pronier, C , Bénézit, F , Reizine, F , Tas, M, et al. Characteristics and outcome of varicella-zoster virus central nervous system infections in adults. Eur J Clin Microbiol Infect Dis. (2021) 40:2437–42. doi: 10.1007/s10096-021-04245-y
68. Herlin, LK , Hansen, KS , Bodilsen, J , Larsen, L , Brandt, C , Andersen, CØ, et al. Varicella zoster virus encephalitis in Denmark from 2015 to 2019-a Nationwide prospective cohort study. Clin Infect Dis. (2021) 72:1192–9. doi: 10.1093/cid/ciaa185
69. Omland, LH , Vestergaard, HT , Dessau, RB , Bodilsen, J , Andersen, NS , Christiansen, CB, et al. Characteristics and long-term prognosis of Danish patients with varicella zoster virus detected in cerebrospinal fluid compared with the background population. J Infect Dis. (2021) 224:850–9. doi: 10.1093/infdis/jiab013
70. Lenfant, T , L’Honneur, AS , Ranque, B , Pilmis, B , Charlier, C , Zuber, M, et al. Neurological complications of varicella zoster virus reactivation: prognosis, diagnosis, and treatment of 72 patients with positive PCR in the cerebrospinal fluid. Brain Behav. (2022) 12:e2455. doi: 10.1002/brb3.2455
71. Yan, Y , Yuan, Y , Wang, J , Zhang, Y , Liu, H , and Zhang, Z . Meningitis/meningoencephalitis caused by varicella zoster virus reactivation: a retrospective single-center case series study. Am J Transl Res. (2022) 14:491–500.
72. Mirouse, A , Sonneville, R , Razazi, K , Merceron, S , Argaud, L , Bigé, N, et al. Neurologic outcome of VZV encephalitis one year after ICU admission: a multicenter cohort study. Ann Intensive Care. (2022) 12:32. doi: 10.1186/s13613-022-01002-y
73. Jennett, B , and Bond, M . Assessment of outcome after severe brain damage. A practical scale. Lancet. (1975) 305:480–4. doi: 10.1016/S0140-6736(75)92830-5
74. Mateen, FJ , Miller, SA , and Aksamit, AJ . Herpes simplex virus 2 encephalitis in adults. Mayo Clin Proc. (2014) 89:274–5. doi: 10.1016/j.mayocp.2013.12.003
75. Whitfield, T , Fernandez, C , Davies, K , Defres, S , Griffiths, M , Hooper, C, et al. Protocol for DexEnceph: a randomised controlled trial of dexamethasone therapy in adults with herpes simplex virus encephalitis. BMJ Open. (2021) 11:e041808. doi: 10.1136/bmjopen-2020-041808
76. Nagel, MA , Niemeyer, CS , and Bubak, AN . Central nervous system infections produced by varicella zoster virus. Curr Opin Infect Dis. (2020) 33:273–8. doi: 10.1097/QCO.0000000000000647
77. Koskiniemi, M , Piiparinen, H , Rantalaiho, T , Eränkö, P , Färkkilä, M , Räihä, K, et al. Acute central nervous system complications in varicella zoster virus infections. J Clin Virol. (2002) 25:293–301. doi: 10.1016/S1386-6532(02)00020-3
78. Lewthwaite, P , Begum, A , Ooi, MH , Faragher, B , Lai, BF , Sandaradura, I, et al. Disability after encephalitis: development and validation of a new outcome score. Bull World Health Organ. (2010) 88:584–92. doi: 10.2471/BLT.09.071357
79. Van Den, TH , Easton, A , Hooper, C , Mullin, J , Fish, J , Carson, A, et al. How should we define a ‘good’ outcome from encephalitis? A systematic review of the range of outcome measures used in the long-term follow-up of patients with encephalitis. Clin Med (Northfield Il). (2022) 22:145–8. doi: 10.7861/clinmed.2021-0505
80. Steiner, I , Budka, H , Chaudhuri, A , Koskiniemi, M , Sainio, K , Salonen, O, et al. Viral meningoencephalitis: a review of diagnostic methods and guidelines for management. Eur J Neurol. (2010) 17:999–e57. doi: 10.1111/j.1468-1331.2010.02970.x
81. Schroth, G , Kretzschmar, K , Gawehn, J , and Voigt, K . Advantage of magnetic resonance imaging in the diagnosis of cerebral infections. Neuroradiology. (1987) 29:120–6. doi: 10.1007/BF00327535
Keywords: viral encephalitis, meningoencephalitis, prognosis, outcome, varicella zoster encephalitis, herpes zoster encephalitis
Citation: Abbuehl LS, Hofmann E, Hakim A and Dietmann A (2023) Can we forecast poor outcome in herpes simplex and varicella zoster encephalitis? A narrative review. Front. Neurol. 14:1130090. doi: 10.3389/fneur.2023.1130090
Edited by:
Til Menge, LVR Klinik Düsseldorf, GermanyReviewed by:
Matthias Maschke, University of Mainz, GermanyThomas Skripuletz, Hannover Medical School, Germany
Copyright © 2023 Abbuehl, Hofmann, Hakim and Dietmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Anelia Dietmann, anelia.dietmann@insel.ch
†ORCID: Eveline Hofmann https://orcid.org/0000-0003-3357-2438
Arsany Hakim https://orcid.org/0000-0001-9431-1069
Anelia Dietmann https://orcid.org/0000-0002-8949-0645